Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9WHMF)

Drug Name
PF-07081532 Drug Info
Synonyms
Lotiglipron; PF-07081532; 2401892-75-7; LOTIGLIPRON [USAN]; YI10W1K93A; SCHEMBL22009794; BDBM450633; EX-A7734; US10676465, Example 10; HY-153865; CS-0865718; 1H-Benzimidazole-6-carboxylic acid, 2-[[4-[(2S)-2-(5-chloro-2-pyridinyl)-2-methyl-1,3-benzodioxol-4-yl]-1-piperidinyl]methyl]-1-[(2S)-2-oxetanylmethyl]-; 2-({4-[(S)-2-(5-Chloropyridin-2-yl)-2-methylbenzo[1,3]dioxol-4-yl]piperidin-1-yl}methyl)-1-{[(S)-oxetan-2-yl]methyl}-1H-benzimidazole-6-carboxylic acid
Indication
Disease Entry ICD 11 Status REF
Obesity 5B81 Phase 2 [1]
Type 2 diabetes 5A11 Phase 2 [1]
Cross-matching ID
PubChem CID
146609022
TTD Drug ID
DM9WHMF

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Glucagon-like peptide 1 receptor (GLP1R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Semaglutide DMAGFOD Type-2 diabetes 5A11 Approved [2]
Liraglutide DM3FXPS Non-insulin dependent diabetes 5A11 Approved [3]
Exenatide DMYHBKN Inflammation 1A00-CA43.1 Approved [4]
Dulaglutide DMYXBV3 Type-2 diabetes 5A11 Approved [5]
Lixisenatide DM0QJDC Type-2 diabetes 5A11 Approved [6]
Pramlintide DM0EZ9Q Type-1/2 diabetes 5A10-5A11 Approved [3]
Albiglutide DM1JEGF Type-2 diabetes 5A11 Approved [6]
Tirzepatide DMQNMAT Type 2 diabetes 5A11 Approved [7]
Efpeglenatide DMKA2PI Type-2 diabetes 5A11 Phase 3 [8]
GLP-1 DMR6YH3 Diabetic complication 5A2Y Phase 3 [2]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glucagon-like peptide 1 receptor (GLP1R) TTVIMDE GLP1R_HUMAN Agonist [1]

References

1 ClinicalTrials.gov (NCT05579977) A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE RANGING, DOSE FINDING, PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF-07081532, AND OPEN LABEL ORAL SEMAGLUTIDE, IN ADULTS WITH TYPE 2 DIABETES MELLITUS (T2DM) INADEQUATELY CONTROLLED ON METFORMIN, AND SEPARATELY PF-07081532 COMPARED TO MATCHING PLACEBO IN ADULTS WITH OBESITY BUT WITHOUT T2DM. U.S.National Institutes of Health.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
3 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
4 Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Diabetes TechnolTher. 2009 Jun;11(6):353-9.
5 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
6 GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.Nat Rev Endocrinol.2012 Dec;8(12):728-42.
7 Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021 Jan 23;106(2):388-396.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)